Can Continuous Levodopa Delivery Be Achieved in the Absence of Intrajejunal Levodopa Infusion? Implications for India and Underserved Countries.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Wiley Country of Publication: United States NLM ID: 101630279 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2330-1619 (Electronic) Linking ISSN: 23301619 NLM ISO Abbreviation: Mov Disord Clin Pract Subsets: MEDLINE
    • Publication Information:
      Original Publication: Hoboken, NJ : Wiley, [2014]-
    • Subject Terms:
      Levodopa* ; Parkinson Disease*/drug therapy; Humans ; Antiparkinson Agents ; Infusions, Parenteral ; India
    • References:
      Transl Neurodegener. 2020 Mar 4;9(1):9. (PMID: 32345378)
      N Engl J Med. 2012 Oct 18;367(16):1529-38. (PMID: 23075179)
      Nat Commun. 2019 Jan 18;10(1):310. (PMID: 30659181)
      J Neurol Sci. 2012 Aug 15;319(1-2):86-8. (PMID: 22632782)
      Eur J Neurol. 2023 May;30(5):1465-1480. (PMID: 36757008)
      Brain Behav. 2022 Sep;12(9):e2547. (PMID: 35943202)
      J Neurol. 2010 Nov;257(Suppl 2):S253-61. (PMID: 21080186)
      J Clin Pharm Ther. 1988 Jun;13(3):191-4. (PMID: 3209626)
      Lancet Neurol. 2022 Dec;21(12):1099-1109. (PMID: 36402160)
      Ann Neurol. 2021 Jul;90(1):52-61. (PMID: 33772855)
      Transl Neurodegener. 2022 Oct 13;11(1):43. (PMID: 36229860)
      Eur Neurol. 2009;62(1):1-8. (PMID: 19407449)
      Parkinsonism Relat Disord. 2014 May;20(5):535-40. (PMID: 24637123)
      J Parkinsons Dis. 2018;8(s1):S65-S72. (PMID: 30584160)
      Clin Neuropharmacol. 1999 Nov-Dec;22(6):351-5. (PMID: 10626097)
      Pharmacoeconomics. 2022 May;40(5):559-574. (PMID: 35307793)
      Neurology. 2004 Jan 13;62(1 Suppl 1):S47-55. (PMID: 14718680)
      Parkinsonism Relat Disord. 2021 Oct;91:139-145. (PMID: 34619438)
      Mov Disord. 2017 Feb;32(2):283-286. (PMID: 27987231)
      Mov Disord. 2015 Jan;30(1):103-13. (PMID: 25335824)
      Mov Disord. 2021 Nov;36(11):2687-2692. (PMID: 34496081)
      Clin Pharmacokinet. 2006;45(2):109-36. (PMID: 16485914)
      Nat Rev Neurosci. 2017 Jul;18(7):435-450. (PMID: 28592904)
      BMC Neurol. 2022 Mar 12;22(1):88. (PMID: 35279112)
      Parkinsonism Relat Disord. 2019 Aug;65:131-138. (PMID: 31176632)
      J Parkinsons Dis. 2022;12(3):975-981. (PMID: 35068418)
      Parkinsonism Relat Disord. 2020 Apr;73:3-7. (PMID: 32179240)
      Ther Adv Neurol Disord. 2022 Jun 26;15:17562864221108018. (PMID: 35785401)
      Ann Indian Acad Neurol. 2021 Sep-Oct;24(5):721-725. (PMID: 35002130)
      Lancet Neurol. 2019 Sep;18(9):865-879. (PMID: 31175000)
      Nat Clin Pract Neurol. 2006 Jul;2(7):382-92. (PMID: 16932589)
      JAMA Intern Med. 2022 Jul 1;182(7):730-738. (PMID: 35639368)
      Mov Disord Clin Pract. 2022 Mar 09;9(3):369-374. (PMID: 35392300)
      Rambam Maimonides Med J. 2010 Jul 02;1(1):e0003. (PMID: 23908775)
      J Neurol Sci. 2016 Jun 15;365:175-80. (PMID: 27206902)
      J Pharmacol Exp Ther. 2014 Oct;351(1):114-23. (PMID: 25073474)
      J Neurochem. 2003 Dec;87(5):1284-95. (PMID: 14622108)
      Sci Rep. 2015 Jun 09;5:11078. (PMID: 26058043)
      Front Neurol. 2021 Jun 15;12:668322. (PMID: 34211431)
      Neurology. 2017 Aug 01;89(5):432-438. (PMID: 28679598)
      Mov Disord. 2018 Nov;33(11):1825-1826. (PMID: 30311268)
      Parkinsonism Relat Disord. 2023 Jul;112:105385. (PMID: 37031010)
      Clin Neuropharmacol. 2004 Nov-Dec;27(6):270-3. (PMID: 15613930)
      Lancet. 1988 Nov 26;2(8622):1260. (PMID: 2903997)
      J Parkinsons Dis. 2011;1(2):197-203. (PMID: 23934921)
      Nat Rev Neurol. 2023 Jun;19(6):333-345. (PMID: 37142796)
      Drugs Aging. 1997 May;10(5):332-40. (PMID: 9143854)
      J Parkinsons Dis. 2018;8(s1):S3-S8. (PMID: 30584159)
      Crit Rev Neurobiol. 1994;9(1):67-89. (PMID: 8828004)
      Mov Disord. 2008 Aug 15;23(11):1567-672. (PMID: 18581482)
      N Engl J Med. 2009 Sep 24;361(13):1268-78. (PMID: 19776408)
      Neurodegener Dis Manag. 2022 Apr;12(2):77-91. (PMID: 35313124)
      Mov Disord. 2022 Apr;37(4):857-864. (PMID: 34997937)
      J Neurol Neurosurg Psychiatry. 1990 Feb;53(2):96-101. (PMID: 2313313)
      Front Aging Neurosci. 2017 Jun 28;9:206. (PMID: 28701947)
      Lancet Neurol. 2019 May;18(5):459-480. (PMID: 30879893)
      Ann Neurol. 2001 Nov;50(5):686-7. (PMID: 11706979)
      Clin Neuropharmacol. 2012 Sep-Oct;35(5):205-7. (PMID: 22821063)
    • Contributed Indexing:
      Keywords: Parkinson's; continuous dopaminergic stimulation; low and middle income countries; underrepresented populations
    • Accession Number:
      46627O600J (Levodopa)
      0 (Antiparkinson Agents)
    • Publication Date:
      Date Created: 20240131 Date Completed: 20240201 Latest Revision: 20241023
    • Publication Date:
      20241023
    • Accession Number:
      PMC10828610
    • Accession Number:
      10.1002/mdc3.13915
    • Accession Number:
      38291849